ESCENDO: Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Oct 16, 2026 - P1 | N=20 | Not yet recruiting | Sponsor: University of Michigan Rogel Cancer Center | Trial completion date: Aug 2031 ➔ Dec 2031 | Initiation date: Aug 2026 ➔ Dec 2026 | Trial primary completion date: Aug 2027 ➔ Dec 2027
Trial completion date • Trial initiation date • Trial primary completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|